Public Market Listing
4568TSE
Live quotes, historical charts, and market capitalization for Daiichi Sankyo are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(12 total)
12Total Assets
3Approved
5Phase 3 / Filed
4Phase 1–2 / Early
7Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | TROP2Antibody–drug conjugate | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | FLT3Small molecule | Acute Myeloid Leukemia | |
| Approved | HER2Antibody–drug conjugate | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | Mineralocorticoid receptorSmall molecule | Type 2 DiabetesHypertension | |
| Phase 3 | B7-H3Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 3 | α2δ-1 subunit of voltage-gated calcium channelsSmall molecule | Diabetic Peripheral Neuropathic Pain | |
| Phase 3 | HER3Antibody–drug conjugate | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | CDH6 (Cadherin-6)Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1/2 | SIRPα (Signal regulatory protein alpha) | Non-Small Cell Lung Cancer | |
| Phase 1/2 | TA-MUC1 (tumor-associated MUC1 glycoform) | Non-Small Cell Lung Cancer | |
| Phase 1/2 | Toll-like receptor 7 (TLR7) (inhibitor) | Systemic Lupus Erythematosus | |
| Phase 1 | HLA-A*02/NY-ESO-1 peptide-MHC complex (tumor) x CD3 (T cells)Multispecific antibody | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.